Other languages Denali Therapeutics Inc.

Equities

DNLI

US24823R1059

Market Closed - Nasdaq Other stock markets 01:30:00 27/04/2024 am IST			5-day change	1st Jan Change
15.43 ^USD	+3.14%		-3.56%	-28.10%

09/04	UBS Adjusts Denali Therapeutics Price Target to $32 From $70, Maintains Buy Rating	MT
03/04	Denali Therapeutics Insider Sold Shares Worth $1,896,250, According to a Recent SEC Filing	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Denali Therapeutics Insider Sold Shares Worth $1,896,250, According to a Recent SEC Filing	03/04
Denali Therapeutics Files Prospectus for Secondary Offering	23/03
Denali Shares Rise on PIPE Deal, Plan to Spin Out Preclinical Small Molecule Portfolio	27/02
Denali Q4 Net Loss Widens; Launching PIPE Deal, Plans to Spin Out Preclinical Small Molecule Portfolio; Shares Jump Pre-Bell	27/02
Denali Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	27/02
Sanofi Informs Denali That Potential ALS Drug Misses Primary Endpoint of Phase 2 Study	20/02
Sanofi : échec d'un essai de phase 2 contre la SLA	16/02
Denali Therapeutics Insider Sold Shares Worth $402,420, According to a Recent SEC Filing	16/02
Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier-Crossing Enzyme Replacement Therapy Programs At Worldsymposium	07/02
Denali Therapeutics Inc. Announces Presentations on Its Investigational Blood-Brain Barrier-Crossing Enzyme Replacement Therapies At the Upcoming 2024 Worldsymposium	01/02
Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases	08/01
Denali Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08/11
Denali Therapeutics Reports Positive Interim Data From Study of Enzyme Replacement Therapy DNL310	30/23/30
Denali Therapeutics Inc. Announces New Interim Data from Phase 1/2 Study of DNL310 in MPS II (Hunter Syndrome) at SSIEM 2023	30/23/30
Denali Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/23/09
Insider Sell: Denali Therapeutics	20/23/20
Pfizer y Flagship Pioneering invertirán 100 millones de dólares en el descubrimiento de fármacos	18/23/18
Pfizer, Flagship Pioneering to invest $100 mln for drug discovery	18/23/18
Denali Therapeutics Says Hunter Syndrome Drug Candidate Showed Reduction in Neuroaxonal Damage Marker	20/23/20
Denali Therapeutics Announces Robust Reduction in Neurofilament Light with DNL310 Treatment in MPS II (Hunter Syndrome)	20/23/20

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Denali Therapeutics Inc.

Equities

DNLI

US24823R1059

Other languages

Filters